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The nitrogen heterocyclic rings, eg. pyrroli-
dine-2,5-dione, pyrrolidin-2-one or imidazolidine-
2,4-dione are known as one of the important struc-
tural fragments appearing in the molecules of cur-
rently available anticonvulsants, eg. ethosuximide,
phenytoin or levetiracetam. They are also core frag-
ments of compounds obtained during studies on the
search of new antiepileptic drugs (1-4). Therefore in
the course of developing new anticonvulsants, in
recent years we have synthesized many of pyrroli-
dine-2,5-diones variously substituted at the nitrogen
atom as well as at the position-3 of the imide ring (5-
11). In the earlier studies, we have reported the syn-
thesis and anticonvulsant activity of N-[(4-
arylpiperazin-1-yl)-alkyl]-3-phenyl-pyrrolidine-2,5-
diones which displayed potent anti-seizure protec-
tion in the maximal electroshock test (12, 13).
Among these, the most active were compounds with
methylene bridge between two nitrogen atoms and
(2-chlorophenyl)- [I], (2-trifluoromethylphenyl)-
[II] and (2-methylphenyl)- [III] moieties at posi-
tion-3 of the imide ring (Fig. 1).
The structure-activity relationship analysis
indicated that anticonvulsant activity was connected
closely with the presence of electron-withdrawing
substituents at the 3-phenyl ring. As a continuation
of our systematic SAR studies in this group of
derivatives, in the present work we have designed
and synthesized a new series of N-[(4-arylpiperazin-
1-yl)-methyl]-3-phenyl-pyrrolidine-2,5-diones
[VIII-XIII] and their analogues with the methyl
group at position-3 of the 3-phenyl ring [XIV-XIX].
Additionally, we have obtained several derivatives
with ethylene or propylene spacer between piper-
azine and imide nitrogen atoms [XX-XV].
Compounds VIII-XXV were synthesized
according to Scheme 1. The starting materials, 2-
phenyl- (IV) and 2-(3-methylphenyl)-(V) succinic
acids were prepared using the methods reported
elsewhere (14, 15). The 3-phenyl- and 3-(3-
methylphenyl)-pyrrolidine-2,5-diones (VI, VII)
were obtained in the cyclization reaction (ca. 190OC,
2 h) of the dicarboxylic acids IV or V with 25%
ammonia. Compounds VIII-XIX were synthesized
by the use of Mannich-type reaction from the appro-
priately substituted 3-phenylpyrrolidine-2,5-diones
(VI, VII), formaldehyde and the corresponding 4-
arylpiperazines. The reaction was performed in
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Abstract: The series of N-[(4-arylpiperazin-1-yl)-alkyl]-3-phenyl- and 3-(3-methylphenyl)-pyrrolidine-2,5-
diones [VIII-XXV] were synthesized and evaluated for anticonvulsant and neurotoxic properties. Initial anti-
convulsant screening was performed in mice, using intraperitoneal (ip) maximal electroshock-induced seizures
(MES) and subcutaneous pentylenetetrazole-induced (scPTZ) seizure threshold tests. The neurotoxicity was
determined applying the rotorod screen. Compounds VIII-XXV revealed protection only in the electrically
induced seizures or were inactive. The most active were Mannich bases of 3-(3-methylphenyl)-pyrrolidine-2,5-
dione with electron-withdrawing substituents at position-3 of 4-arylpiperazine fragment [XVII, XVIII], as well
as compounds with ethylene or propylene spacer between imide and 4-arylpiperazine nitrogen atoms [XX-
XXII, XXV]. All these compounds showed anti-MES protection in mice at doses of 100 mg/kg. Additionally,
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Scheme 1. Synthesis of compounds VI-XXV.
Reagents and conditions: (a) 25% NH4OH, 190OC, 2 h; (b) 4-arylpiperazine derivatives, formaldehyde, 96% ethyl alcohol, reflux for 0.5 h
or ca. 6-12 h room temp; (c) 1-aminoalkyl-4-arylpiperazine, cyclocondensation, 190OC, 2 h; (d) anhydrous ethanol + HCl 
Figure 1. Chemical structures of compounds I-III.
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Table 1. Physicochemical and analytical data for compounds VI-XXV.
Compd. 
Molecular Yield % Analysis
Rfaformula/Weight m.p. [OC] %C %H %N
VI C10H9O2N 70 68.64 5.18 8.00 0.42 (S1)
175.19 78-80 68.90 5.27 7.83   
VII C11H11O2N 60 69.91 5.87 7.41 0.53 (S1)
189.17 91-93 70.03 6.00 7.66   
VIII C21H23O2N3 72 72.17 6.63 12.03 0.70 (S2)
349.44 154-156 72.16 6.71 12.12   
IX C21H22O2N3F 81 68.65 6.04 11.44 0.65 (S2)
367.43 93-94 68.55 6.24 11.23   
X C21H22O2N3Cl 73 65.70 5.78 10.95 0.66 (S2)
383.88 102-104 65.75 5.81 11.01  
XI C21H22O2N3Cl 73 65.70 5.78 10.95 0.63 (S2)
383.88 114-116 65.78 5.77 10.90   
XII C22H22O2N3F3 79 63.30 5.31 10.07 0.69 (S2)
417.44 116-117 63.18 5.42 10.20   
XIII C22H25O2N3 84 72.69 6.93 11.56 0.72 (S2)
363.46 102-103 72.35 6.97 11.44   
XIV C22H25O2N3 69 72.69 6.93 11.56 0.61 (S2)
363.46 82-84 72.62 6.87 11.62   
XV C22H24O2N3F 83 69.27 6.34 11.02 0.63 (S2)
381.45 118-120 69.17 6.13 11.00   
XVI C22H24O2N3Cl 82 66.41 6.08 10.56 0.69 (S2)
397.90 85-87 66.35 6.27 10.53   
XVII C22H24O2N3Cl 63 66.39 6.08 10.56 0.72 (S2)
397.90 132-134 66.34 6.01 10.55   
XVIII C23H24O2N3F3 75 64.03 5.61 9.74 0.94 (S2)
431.46 80-82 63.95 5.70 9.66   
XIX C23H27O2N3 65 73.18 7.21 11.13 0.68 (S2)
377.49 91-93 73.11 7.11 11.12   
XX C23H25O2N3ClF3 70 59.04 5.39 8.98 0.79 (S2) 
467.92 210-212 58.98 5.62 8.80  
XXI* C23H29O2N3Cl2 58 61.33 6.49 9.33 0.79 (S2)
450.41 191-193 61.30 6.38 9.21   
XXII C23H28O2N3Cl 65 66.74 6.82 10.15 0.91 (S2) 
413.95 190-192 66.92 7.02 9.95  
XXIII C23H27O2N3ClF 65 63.96 6.30 9.73 0.80 (S2) 
431.94 179-181 63.78 6.18 9.55  
XXIV C23H27O2N3Cl 62 61.61 6.07 9.37 0.85 (S2)
190.20 178-180 61.45 6.00 9.21   
XXV C24H29O2N3Cl2 68 62.40 6.33 9.10 0.82 (S2) 
462.43 180-182 62.62 6.17 9.30  
a) Developing system: S1 ñ chloroform: acetone (9 : 1, v/v), S2 ñ chloroform : 2-propanol : 25% ammonia (9 : 11 : 2, v/v/v). 
* Physicochemical data from Ref. (17)
ethanol at room temperature for ca. 6-12 h.
Additionally, in several cases the reaction mixture
was refluxed for 0.5 h.
Compounds XX-XXV were prepared using a
one-pot cyclization reaction of IV or V with appro-
priately substituted 1-(2-aminoethyl)- or 1-(3-
aminopropyl)-4-arylpiperazines, by heating them at
ca. 190OC for 2 h. Because of the oily form of com-
pounds XX-XXV they were isolated as hydrochlo-
ride salts.
The 1-(2-aminoethyl)- and 1-(3-aminopropyl)-
4-arylpiperazines were prepared according to the
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procedure described elsewhere (16). The synthesis
and physicochemical data of XXI have been
described previously (17). This molecule was not
tested for its anticonvulsant activity
The structures of VI-XXV were confirmed by
the elemental analysis and by the examination of 1H
NMR spectra. 
The 1H NMR spectra revealed characteristic
chemical shifts. The protons of imide rings (Ha, Hm,
Hx) were separated and revealed the known AMX
system. The signals of Ha protons were observed as
doublet of doublets within the range from δ 2.67 to
3.02 ppm [VI, VII, X-XIV, XVI, XVIII, XX-XXV]
or as doublets at about δ 2.90 ppm [XVII, VIII, XV,
and XIX]. The Hm protons were recorded as doublet
of doublets within the range δ 3.23 to 3.32 ppm [VI-
XV and XXV], as doublets at δ 3.25 [XVI, XVII]
and at δ 3.26 ppm [XIX] or as multiplets within the
range δ 3.38-3.74 ppm [XVIII, XX-XXIV]. For all
compounds the resonance signals of Hx protons were
shown as quartets ranging from δ 4.01 to 4.82 ppm.
The protons of methylene group [VIII-XII, XIV and
XV] appeared as triplets at δ 4.60 ppm or as singlets
for compounds XIII and XIV-XIX. The piperazine
protons were observed as multiplets or broad singlets
at about δ 2.80 ppm and δ 3.70 ppm. The resonance
signals of methyl groups [XV-XIX and XXII-XV]
were shown as singlets ranging from δ 2.34 ppm to δ
2.40 ppm. All aromatic protons were well separated
and were observed within a range of δ 6.60-7.42
ppm. For the details see Tables 2, 3 and 4.
EXPERIMENTAL
Chemistry
All the chemicals and solvents were purchased
from Merck (Darmstadt, Germany) and were used
without further purification. Melting points (m.p.)
were determined in open capillaries on a B¸chi 353
melting point apparatus (B¸chi Labortechnik, Flawil,
Switzerland) and are uncorrected. The purity of the
compounds was confirmed by the thin-layer chro-
matography (TLC) on Merck silica gel 60 F254 alu-
minium sheets (Merck; Darmstadt, Germany), using
the developing systems: S1 ñ chloroform : acetone (9
: 1, v/v). S2 ñ chloroform : 2-propanol : 25% ammo-
nia (9 : 11 : 2, v/v/v). Spots were detected by their
absorption under UV light (λ = 254 nm)   and by
visualization with 0.05 mol I2 in 10% HCl. The
chemical structures were confirmed by elemental
Table 2. 1H-NMR data of compounds VI-XIII.
Cmpd 1H NMR δ (ppm) / CDCl3
VI 
2.90 (dd, 1H, Ha imide, J = 5.13 Hz, J = 18.72 Hz), 3.26 (dd, 1H, Hm imide, J = 9.50 Hz, J = 18.46 Hz), 
4.10 (q, 1H, Hx imide, J = 5.13 Hz), 7.27-7.42 (m, 5H, ArH)  
2.35 (s, 3H, CH3), 2.87 (dd, 1H, Ha imide, J = 5.13 Hz, J = 18.72 Hz), 3.24 (dd, 1H, Hm imide, J = 9.75 
VII Hz, J = 18.72 Hz), 4.04 (q, 1H, Hx imide, J = 5.13 Hz), 7.27-7.42 (m, 5H, ArH), 7.03-7.05 (m, 2H, ArH),
7.15 (t, 1H, ArH, J = 7.45 Hz), 7.27-7.30 (m, 1H, ArH)  
2.91 (d, 1H, Ha imide, J = 5.13 Hz), 2.77-2.86 (m, 4H, piperazine), 3.17-3.17 (m, 4H, piperazine), 3.23 
VIII (dd, 1H, Hm imide, J = 9.75 Hz, J = 18.50 Hz), 4.05 (q, 1H, Hx imide, J = 4.62 Hz), 4.61 (t, 2H, CH2, 
J = 13.59 Hz), 6.84-6.92 (m, 3H, ArH), 7.22-7.41 (m, 7H, ArH)  
2.81-2.87 (m, 4H, piperazine), 2.92 (d, 1H, Ha imide, J = 5.13 Hz), 3.06-3.13 (m, 4H, piperazine), 3.25 
IX (dd, 1H, Hm imide, J = 9.74 Hz, J = 18.46 Hz), 4.07 (q, 1H, Hx imide, J = 5.13 Hz), 4.60 (t, 2H, CH2, 
J = 13.33 Hz), 6.90-7.08 (m, 4H, ArH), 7.24-7.42 (m, 5H, ArH)  
2.77-2.83 (m, 4H, piperazine), 2.90 (dd, 1H, Ha imide, J = 4.87 Hz, J = 18.72 Hz), 3.15-3.19 (m, 4H, 
X
piperazine), 3.24 (dd, 1H, Hm imide, J = 9.49 Hz, J = 18.46 Hz), 4.06 (q, 1H, Hx imide, J = 5.0 Hz), 4.60 
(t, 2H, CH2, J = 13.59 Hz), 6.74-6.85 (m, 3H, ArH), 7.16 (t, 1H, ArH, J = 8.08 Hz), 7.22-7.41 (m, 5H, 
ArH)  
2.76-2.79 (m, 4H, piperazine), 2.89 (dd, 1H, Ha imide, J = 5.13 Hz, J = 18.46 Hz), 3.12-3.15 (m, 4H, 
XI piperazine), 3.24 (dd, 1H, Hm imide, J = 9.74 Hz, J = 18.72 Hz), 4.05 (q, 1H, Hx imide, J = 5.13 Hz), 4.60
(t, 2H, CH2, J = 13.34 Hz), 6.80-6.83 (m, 2H, ArH), 7.17-7.22 (m, 4H, ArH), 7.28-7.40 (m, 3H, ArH)  
2.79-2.81 (m, 4H, piperazine), 2.89 (dd, 1H, Ha imide, J = 5.13 Hz, J = 18.98 Hz), 3.20 (brs, 4H, 
XII piperazine), 3.27 (dd, 1H, Hm imide, J = 9.74 Hz, J = 18.46 Hz), 4.06 (q, 1H, Hx imide, J = 5.13 Hz), 
4.61 (t, 2H, CH2, J = 13.34 Hz), 7.02-7.09 (m, 3H, ArH), 7.22-7.26 (m, 2H, ArH), 7.31-7.40 (m, 4H, ArH)
2.31 (s, 3H, CH3), 2.79 (brs, 4H, piperazine), 2.88 (dd, 1H, Ha imide, J = 5.13 Hz, J = 18.46 Hz), 
XIII
3.14-3.18 (m, 4H, piperazine), 3.24 (dd, 1H, Hm imide, J = 9.74 Hz, J = 18.46 Hz), 4.06 (q, 1H, Hx imide, 
J = 5.00 Hz), 4.60 (s, 2H, CH2), 6.61-6.75 (m, 3H, ArH), 7.13-7.17 (m, 1H, ArH), 7.22-7.26 (m, 2H, ArH),
7.31-7.40 (m, 3H, ArH) 
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and spectral analyses (1H NMR). 1H NMR spectra
were obtained in a Varian Mercury 300 MHz spec-
trometer (Varian Inc., Palo Alto, CA, USA), in
CDCl3, with TMS as an internal standard. Chemical
shifts are reported in δ values (ppm) and J values in
Hertz (Hz). Signal multiplicities are represented by
the following abbreviations: s (singlet), brs (broad
singlet), d (doublet), dd (doublet of doublets), t
(triplet), q (quartet), m (multiplet). Elemental analy-
ses C, H, N were carried out with an Elementar Vario
EL III (Hanau, Germany) and were within ± 0.4% of
the theoretical values. The physicochemical data,
yields, elemental analyses and Rf values for com-
pounds VI-XXV are presented in Table 1. The 1H
NMR data are shown in Tables 2-4.
General procedure for the synthesis of 3-phenyl- and
3-(methylphenyl)-pyrrolidine-2,5-diones (VI, VII)
A total of 0.05 mol of the 2-phenyl- (IV) or 2-
(3-methylphenyl)- (V) succinic acids were dissolved
in 50 mL of water and 0.05 mol of a 25% ammonia
was gradually added. The mixture was heated in an
oil bath with simultaneous distillation of water. The
cyclization reaction was continued at 190OC for 2 h.
The solid products were separated by filtration and
crystallized from methanol.




The mixture of 3-phenyl- (0.01 mol) (VI) or 3-
(3-methylphenyl)-pyrrolidine-2,5-dione (0.01 mol)
(VII), 40% formaldehyde (0.01 mol) and correspon-
ding 4-arylpiperazines (0.01 mol) in 96% ethanol
(40 mL) was left for 6-12 h at room temperature
(additionally refluxed for compounds XIV and XX),
then refrigerated at ca. -10OC for 24 h. The solid
products (VIII-XIII, and XIV-XIX) were separated
by filtration and recrystallized from 96% ethanol.
General procedure for the synthesis of N-[(4-
arylpiperazin-1-yl)-alkyl]-3-phenyl- (XX, XXI) and
3-(3-methylphenyl)-pyrrolidine-2,5-diones (XII-
XXV)
A total of 0.01 mol of the appropriately substi-
tuted 1-(2-aminoethyl)- or 1-(3-aminopropyl)-4-
arylpiperazines were mixed with 20 mL of water,
and 0.01 mol of the 2-phenyl- (IV) or 2-(3-
methylphenyl)- (V) succinic acid was gradually
added. The mixture was heated in an oil bath with
simultaneous distillation of water. The cyclization
reaction was continued in 190OC for 2 h. Free bases,
Table 3. 1H-NMR data of compounds XIV-XX.
Compd. 1H NMR δ (ppm) / CDCl3
2.43 (s, 3H, CH3), 2.80-2.82 (m, 4H, piperazine), 2.88 (dd, 1H, Ha imide, J = 4.87 Hz, J = 18.46 Hz), 
XIV
3.16-3.20 (m, 4H, piperazine), 3.23 (dd, 1H, Hm imide, J = 9.74 Hz, J = 18.72 Hz), 4.01 (q, 1H, Hx
imide, J = 5.00 Hz), 4.60 (t, 2H, CH2, J = 13.08 Hz), 6.85-6.93 (m, 3H, ArH), 7.01-7.05 (m, 2H, ArH), 
7.11-7.24 (m, 1H, ArH), 7.27-7.30 (m, 3H, ArH)  
2.35 (s, 3H, CH3), 2.85 (brs, 4H, piperazine), 2.91 (d, 1H, Ha imide, J = 87 Hz), 3.07-3.10 (m, 4H, 
XV
piperazine), 3.23 (dd, 1H, Hm imide, J = 9.74 Hz, J = 18.46 Hz), 4.03 (q, 1H, Hx imide, J = 4.87 Hz), 
4.61 (t, 2H, CH2, J = 13.08 Hz), 6.90-6.99 (m, 2H, ArH), 7.02-7.08 (m, 3H, ArH), 7.11-7.29 (m, 3H, 
ArH)  
2.34 (s, 3H, CH3), 2.75-2.78 (m, 4H, piperazine), 2.87 (dd, 1H, Ha imide, J = 4.87 Hz, J = 18.72 Hz), 
XVI 3.15-3.20 (m, 4H, piperazine), 3.25 (d, 1H, Hm imide, J = 9.75 Hz), 4.11 (q, 1H, Hx imide, J = 4.87 Hz),
4.59 (s, 2H, CH2), 6.73-6.85 (m, 3H, ArH), 7.00-7.28 (m, 5H, ArH)  
2.34 (s, 3H, CH3), 2.78-2.85 (m, 4H, piperazine), 2.90 (d, 1H, Ha imide, J = 4.87 Hz), 3.12-3.20 (m, 4H, 
XVII piperazine), 3.25 (d, 1H, Hm imide, J = 9.49 Hz), 4.01 (q, 1H, Hx imide, J = 4.87 Hz), 4.59 (s, 2H, CH2), 
6.81 (d, 2H, ArH, J = 8.98 Hz), 7.00-7.04 (m, 2H, ArH), 7.11-7.28 (m, 4H, ArH)  
2.35 (s, 3H, CH3), 3.02 (dd, 1H, Ha imide, J = 5.13 Hz, J = 18.72 Hz), 3.38-3.47 (m, 5H, 4H piperazine, 
XVIII 1H, Hm imide), 3.70 (brs, 4H, piperazine), 4.25 (q, 1H, Hx imide, J = 5.64 Hz), 4.82 (s, 2H, CH2), 7.06-
7.30 (m, 7H, ArH), 7.43 (t, 1H, ArH, J = 7.95 Hz)  
2.33 (d, 6H, 2xCH3, J = 8.21 Hz), 2.84 (brs, 4H piperazine), 2.91 (d, 1H, Ha imide, J = 4.87 Hz), 3.17-
XIX
3.22 (m, 4H, piperazine), 3.26 (d, 1H, Hm imide, J = 9.49 Hz), 4.02 (q, 1H, Hx imide, J = 4.87 Hz), 
4.60 (s, 2H, CH2), 6.65-6.85 (m, 3H, ArH), 7.03 (d, 2H, ArH, J = 8.97 Hz), 7.14 (t, 2H, ArH, J = 7.58 
Hz), 7.24-7.30 (m, 1H, ArH)  
2.83 (dd, 1H, Ha imide, J = 4.62 Hz, J = 18.46 Hz), 2.93-2.96 (m, 2H, CH2-CH2), 3.36-3.38 (m, 2H, 
XX piperazine), 3.61-3.67 (m, 3H, 1H, Hm imide, 2H, CH2-CH2), 3.70-3.80 (m, 2H, piperazine), 3.93-4.05
(m, 4H, piperazine), 4.57 (q, 1H, Hx imide, J = 4.87 Hz), 7.06-7.60 (m, 9H, ArH), 12.51 (brs, 1H, HCl)  
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obtained as light oils, were converted to hydrochlo-
ride salts in anhydrous ethanol saturated with HCl
gas. The obtained precipitates were crystallized
from anhydrous ethanol.
Pharmacology
Compounds VIII-XXV were pharmacological-
ly pre-evaluated within the Antiepileptic Drug
Development (ADD) Program in Epilepsy Branch,
National Institutes of Health, National Institute of
Neurological Disorders and Stroke (NIH/NINDS),
Rockville, MD, USA, by using procedures
described elsewhere (18).
Male albino mice (CFñ1 strain) and male albi-
no rats (SpragueñDawley) were used as experimen-
tal animals. The animals were housed in metabolic
cages and allowed free access to food and water.
The compounds were suspended in 0.5% methylcel-
lulose/water mixture.
Phase I studies in mice involved two convulsant
testes: maximal electroshock seizure test (MES),
subcutaneous pentylenetetrazole seizure test (scPTZ)
and rotorod test for neurological toxicity (NT).
The maximal electroshock test (MES)
In the MES screen, an electrical stimulus of 0.2
s in duration (50 mA in mice and 150 mA in rat at
60 Hz) is delivered via corneal electrodes primed
with an electrolyte solution containing an anesthetic
agent.
The subcutaneous pentylenetetrazole seizure test
(scPTZ)
This screen utilizes a dose of pentylenetetra-
zole (85 mg/kg in mice and 70 mg/kg in rats) that
produces clonic seizures lasting for a period of at
least five seconds in 97% (CD97) of animals tested.
At the anticipated time of testing the convulsant is
administered subcutaneously.
All the compounds were injected intraperi-
toneally into mice at the dose levels of 30, 100, and
300 mg/kg with anticonvulsant activity and neuro-
toxicity assessment at 0.5 and 4 hours after adminis-
tration.
The neurological toxicity (NT) induced by a
compound was detected in mice or rats using stan-
dardized rotorod test (19). Untreated control mice or
rats, when placed on the rod, can maintain their
equilibrium for a prolonged time period. The acute
motor impairment can be demonstrated by the
inability of animal to maintain equilibrium for a
given time.
The results of preliminary screening for com-
pounds VIII-XXV are presented in Tables 5 and 6. 
According to the ASP dispositions compound
XVIII was administrated orally into rats at a fixed
dose of 30 mg/kg (MES test). This screen discloses
the time of onset, the approximate time of peak
effect (TPE) and the duration of anticonvulsant
activity. At the same doses, the motor impairment
was studied in parallel. Rats were tested at five time
Table 4. 1H-NMR data of compounds XXI-XXV.
Cmpd 1H NMR δ (ppm) / CDCl3
2.06 (t, 2H, CH2-CH2-CH2, J = 7.60 Hz), 2.67 (dd, 1H, Ha imide, J = 4.87 Hz, J =18.20 Hz), 2.99 (brs, 2H, 
XXI*
-CH2-CH2-CH2), 3.36 (d, 2H, CH2-CH2-CH2, J = 5.39 Hz), 3.60-3.74 (m, 5H, 4H piperazine, 1H, Hm
imide), 3.95-4.06 (m, 4H, piperazine), 4.82 (q, 1H, Hx imide, J = 4.62 Hz), 6.93-7.32 (m, 9H, ArH), 12.72 
(brs, 1H, HCl)  
2.34 (s, 3H, CH3), 2.71 (dd, 1H, Ha imide, J = 4.67 Hz, J = 18.43 Hz), 2.96 (brs, 2H, CH2-CH2), 3.32-3.59 
XXII
(m, 2H, CH2-CH2), 3.62-3.69 (m, 5H, 4H piperazine, 1H, Hm imide), 3.98 (brs, 4H, piperazine), 4.52 (q, 
1H, Hx imide, J = 4.67 Hz), 6.92-6.99 (m, 2H, ArH), 7.04-7.21 (m, 2H, ArH), 7.22-7.32 (m, 5H, ArH), 
12.70 (brs, 1H, HCl)  
2.34 (s, 3H, CH3), 2.80 (dd, 1H, Ha imide, J = 4.36 Hz, J = 18.21 Hz), 3.00 (d, 2H, CH2-CH2, J = 8.98 Hz), 
XXIII 3.36-3.59 (m, 4H, piperazine), 3.60-3.73 (m, 3H, 2H, CH2-CH2, 1H, Hm imide), 3.98 (brs, 4H, piperazine), 
4.53 (q, 1H, Hx imide, J = 4.36 Hz), 6.95-7.11 (m, 6H, ArH), 7.21-7.26 (m, 2H, ArH), 12.44 (brs, 1H, HCl)  
2.40 (s, 3H, CH3), 2.68 (dd, 1H, Ha imide, J = 4.62 Hz, J = 18.20 Hz), 2.93 (d, 2H, CH2-CH2, J = 8.72 Hz), 
XXIV
3.35-3.40 (m, 2H, CH2-CH2,), 3.60-3.95 (m, 5H, 1H, Hm imide, 4H, piperazine), 3.98-4.07 (m, 4H, 
piperazine), 4.82 (q, 1H, Hx imide, J = 4.87 Hz), 7.04-7.23 (m, 7H, ArH), 7.39 (t, 1H, ArH, J = 7.95 Hz), 
12.88 (brs, 1H, HCl)  
1.61 (brs, 2H, (m, 2H, CH2-CH2-CH2), 2.33-2.36 (m, 4H, piperazine), 2.39 (s, 3H, CH3), 2,89 (dd, 1H, Ha
imide, J = 4.68 Hz, J = 18.40 Hz), 3.08 (brs, 2H, CH2-CH2-CH2), 3.32 (dd, 1H, Hm imide, J = 9.63 Hz, 
XXV J = 18.70 Hz), 3.65 (brs, 4H, piperazine), 3.75 (t, 2H, CH2-CH2-CH2, J = 6.33 Hz), 4.12 (q, 1H, Hx imide, 
J = 4.68 Hz), 6.79-6.82 (m, 1H, ArH), 6.92 (t, 1H, ArH, J= 2.20 Hz), 6.95-7.08 (m, 2H, ArH), 7.14-7.32 
(m, 4H, ArH), 12.80 (brs, 1H, HCl)  * Data from Ref. (17)
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Table 5. Anticonvulsant screening project (ASP), results in mice for compounds VIII-XIX.
Intraperitoneal injection in mice
Compound R R1 MESa NTb
0.5 h 4 h 0.5 h 4 h
VIII H H - - 100 300
IX H 2-F - - 3001 -
X H 3-Cl - - 300 -
XI H 4-Cl - - - -
XII H 3-CF3 - - - -
XIII H 3-CH3 - - 30 -
XIV CH3 H - - 30 -
XV CH3 2-F - - 300 300
XVI* CH3 3-Cl - 300 - -
XVII CH3 4-Cl - 100 - 300
XVIII CH3 3-CF3 300 100 30014 -
XIX CH3 3-CH3 - - 100 -
Phenytoinc - - 30 30 100 100  
a) Doses of 30, 100 and 300 mg/kg were administrated. The values in the table indicate the minimum dose (mg/kg), whereby bioactivity
was demonstrated. The dash (-) indicates an absence of activity at maximum dose administrated. b) Toxicity screen: the minimum dose of
compound whereby toxicity was exhibited. c) Reference drug, data from Ref. (21). Response comments: 1 death, 14 unable to grasp rotorod.
* Compounds XVI revealed anti-MES activity at a dose of 100 mg/kg at 6 h
Table 6. Anticonvulsant screening project (ASP), results in mice for compounds XX-XXV.
Intraperitoneal injection in mice
Compound R R1 n       MESa NTb
0.5 h 4 h 0.5 h 4 h  
XX H 3-CF3 2 100 100 300 300  
XXI H H 3 - 100 1001 -  
XXII CH3 H 2 - 100 - -  
XXIII CH3 2-F 2 - - - -  
XXIV CH3 3-Cl 2 - - - -  
XXV* CH3 3-Cl 3 300 100 301
Phenytoinc 30 30 1001
For a), b), c) and Response comments see Table 5. *Compound XXV revealed anti-MES activity at a dose of 100 mg/kg at 6 h
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periods ranging from one quarter to 4 h post sub-
stance administration. The results are shown in
Table 7.
RESULTS
The anticonvulsant profile of compounds VIII-
XXV was established in the maximal electroshock
(MES) and subcutaneous pentylenetetrazole
(scPTZ) tests, after intraperitoneal injection into
mice at doses of 30, 100 and 300 mg/kg. An obser-
vation was carried out at two different time inter-
vals, namely 0.5 h and 4 h. The acute neurological
toxicity (NT) was determined in the minimal motor
impairment-rotorod screen (NT). 
The MES and scPTZ tests are claimed to detect
compounds affording protection against generalized
tonic-clonic seizures and generalized absence
seizures, respectively. Thus they are recognized as
the ìgold standardsî on the early stages of testing of
new anticonvulsants (20). As shown in Tables 5 and
6, compounds VIII-XXV revealed protection only
in the electrically induced seizures or were inactive.
In this series, the most active were compounds
XVII, XVIII, XX-XXII and XXV, which showed
anti-MES activity at doses of 100 mg/kg both at 0.5
h and 4 h (XX) or only at 4 h (XVII, XVIII, XXI
and XXII) after intraperitoneal injection in mice.
Compounds XVIII and XXV revealed also protec-
tion at a dose of 300 mg/kg at 0.5 h. It is noteworthy
that XXV active at a doses 100 mg/kg and 300
mg/kg was toxic at a dose of 30 mg/kg (mice were
unable to grasp rotorod). The further results indicat-
ed that XVI was less active and provided protection
at a dose of 300 mg/kg at 4 h. This compound was
also effective at a dose of 100 mg/kg at 6 h. All the
N-[(4-arylpiperazin-1-yl)-methyl]-3-phenyl-pyrroli-
dine-2,5-diones (VIII-XIII) as well as XIV, XV,
XIX, XXIII and XXIV were devoid of activity.
The results from the rotorod neurotoxicity
evaluations demonstrated that only five compounds,
namely XI, XII, XVI, XXIII and XIV, did not cause
neurotoxicity at the maximal dose administrated ñ
300 mg/kg. The other derivatives were found to be
neurotoxic at a dose of 30 mg/kg (XIII, XIV and
XXV), 100 mg/kg (VIII, XIX, XXI) or 300 mg/kg
(IX, X, XV, XVII, XVIII and XX).
Compound XVIII was examined for its anti-
convulsant activity and neurotoxicity in rat oral
screen at a dose of 30 mg/kg in MES test (Table 7).
This molecule revealed 50% protection at time point
1 h and 25% protection at 0.5 h. When given orally,
XVIII was not neurotoxic. This compound was less
active than phenytoin, used as reference substance
for anticonvulsants effective in the electrically
induced seizures.
In conclusion, among compounds studied the
most active was N-[{4-(3-trifluoromethylphenyl)-
piperazin-1-yl}-methyl]-3-(3-methylphenyl)-pyrro-
lidine-2,5-dione [XVIII], obtained as close ana-
logue of model compound III. In the investigated
series of compounds, the anticonvulsant activity
depended on the presence of methyl group at the 3-
phenyl moiety, the kind of substituents at the 4-
arylpiperazine fragments, as well as the length of
alkyl spacer between the imide and piperazine nitro-
gen atoms. In relation to Mannich bases VIII-XIX,
the most active were 3-methylphenyl-pyrrolidine-
2,5-diones containing the electron-withdrawing
groups at the 4-arylpiperazine, in general.
Interestingly, the removal of the 3-methyl group
yielded inactive analogues. On the other hand, the
elongation of the alkyl chain between the imide and
piperazine nitrogen atoms from the methylene to
ethylene or propylene increased the activity among
the 3-phenyl-pyrrolidine-2,5-diones, in contrast to
the 3-methyl analogues.
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Table 7. Anticonvulsant activity (MES test) of compound XVIII administrated orally to rats.
Compound Oral administration to ratsa
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ref. (21)
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